Aktis Oncology(AKTS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

AKTS Aktis Oncology

Pre-Mkt 04-28 04:46:21 EDT

20.09

-1.17

-5.50%

High22.40	Low19.86	Vol218.68K
Open21.02	D1 Closing21.26	Amplitude11.95%
Mkt Cap1.11B	Tradable Cap354.59M	Total Shares55.28M
T/O4.51M	T/O Rate1.24%	Tradable Shares17.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"AKTS","market":"US","secType":"STK","nameCN":"Aktis Oncology","latestPrice":20.09,"timestamp":1777320000000,"preClose":21.26,"halted":0,"volume":218682,"delay":0,"changeRate":-0.05503292568203206,"floatShares":17650000,"shares":55276000,"eps":-1.155,"marketStatus":"Pre-Mkt","change":-1.17,"latestTime":"04-28 04:46:21 EDT","open":21.02,"high":22.4,"low":19.86,"amount":4513597.495518,"amplitude":0.119473,"askPrice":22.58,"askSize":100,"bidPrice":8.05,"bidSize":60,"shortable":3,"etf":0,"ttmEps":-1.155,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1777383000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1767934800000,"exchange":"NASDAQ","adjPreClose":20.09,"postHourTrading":{"tag":"盘后","latestPrice":20.1,"preClose":20.09,"latestTime":"16:42 EDT","volume":3065,"amount":61576.58,"timestamp":1777322554810,"change":0.01,"changeRate":0.000498,"amplitude":0.000498},"volumeRatio":0.8209370424597364,"impliedVol":1.5345,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/AKTS","defaultTab":"news","newsList":[{"id":"2629063666","title":"Aktis Oncology Announces Presentation of First Clinical Imaging and Dosimetry Data for AKY-2519 at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629063666","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629063666?lang=en_us&edition=fundamental","pubTime":"2026-04-22 05:00","pubTimestamp":1776805200,"startTime":"0","endTime":"0","summary":"AKY-2519, a miniprotein radioconjugate targeting B7-H3, to be featured in two poster presentationsData facilitate initial understanding of AKY-2519 biodistribution and predicted absorbed doses in tumo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/21/3278532/0/en/Aktis-Oncology-Announces-Presentation-of-First-Clinical-Imaging-and-Dosimetry-Data-for-AKY-2519-at-the-2026-American-Society-of-Clinical-Oncology-ASCO-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BK4139","AKTS","BK4107","AFG","BK4117","BK4148"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628763734","title":"Aktis Oncology Board Shift And New Committee Draw Investor Focus On R&D","url":"https://stock-news.laohu8.com/highlight/detail?id=2628763734","media":"Simply Wall St.","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628763734?lang=en_us&edition=fundamental","pubTime":"2026-04-19 13:03","pubTimestamp":1776575011,"startTime":"0","endTime":"0","summary":"Aktis Oncology (NasdaqGS: AKTS) has appointed Dr. Glenn Gormley as an independent director to its Board.\nDr. Gormley will also serve as co-chair of a newly formed Science and Technology Committee.\nThe company announced upcoming departures of two current Board members as part of this transition.\n\nAktis Oncology, trading on NasdaqGS under the ticker AKTS, recently closed at $20.25. The stock is up 20.0% over the past week and 14.4% over the past 30 days, while the year-to-date return stands at...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-akts/aktis-oncology/news/aktis-oncology-board-shift-and-new-committee-draw-investor-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-akts/aktis-oncology/news/aktis-oncology-board-shift-and-new-committee-draw-investor-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["AKTS","BK4148","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628724622","title":"Aktis Oncology director Glenn Gormley files initial beneficial ownership statement","url":"https://stock-news.laohu8.com/highlight/detail?id=2628724622","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628724622?lang=en_us&edition=fundamental","pubTime":"2026-04-17 04:05","pubTimestamp":1776369958,"startTime":"0","endTime":"0","summary":"Aktis Oncology filed an initial Form 3 for director Glenn Gormley dated April 15, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aktis Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDLbHbhz7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4148","AKTS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627021219","title":"Aktis Oncology appoints Gormley as independent director of Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2627021219","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627021219?lang=en_us&edition=fundamental","pubTime":"2026-04-16 22:16","pubTimestamp":1776348974,"startTime":"0","endTime":"0","summary":"Aktis Oncology (AKTS) announced the appointment of Glenn Gormley, MD, PhD, as an independent director to its Board of Directors and co-chair of the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aktis-oncology-appoints-gormley-as-independent-director-of-board-of-directors-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aktis-oncology-appoints-gormley-as-independent-director-of-board-of-directors-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AKTS","BK4148"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627996290","title":"Press Release: Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2627996290","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627996290?lang=en_us&edition=fundamental","pubTime":"2026-04-16 20:00","pubTimestamp":1776340800,"startTime":"0","endTime":"0","summary":"Dr. Gormley brings more than three decades of biopharmaceutical leadership across research and development, executive leadership, and board service. Most recently, Dr. Gormley served as Senior Executive Officer and Global Head of Research and Development at Daiichi Sankyo Co., Ltd., and as Executive Chairman and President of Daiichi Sankyo, Inc. In these roles, he led the global R&D strategy and oversaw the development of a broad and diversified pipeline, including the successful build-out of Daiichi Sankyo's ADC platform. Prior to Daiichi Sankyo, Dr. Gormley held senior leadership positions at several global pharmaceutical companies. He served as Chief Medical Officer at AstraZeneca and as Global Head of Clinical Development and Medical Affairs at Novartis, where he led late-stage development and medical strategy across multiple programs. Earlier in his career, he held senior clinical development roles at Merck. Dr. Gormley holds an MD and a PhD from the University of Chicago and comp","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MD","BK4148","BK4139","ADC","AKTS","BK4196","BK4231","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623583133","title":"Aktis Oncology Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2623583133","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623583133?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:04","pubTimestamp":1774955040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AKTS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 31, 2026 07:04 ET (11:04 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623583378","title":"Aktis Oncology Inc : Leerink Partners Raises Target Price to $33 From $31","url":"https://stock-news.laohu8.com/highlight/detail?id=2623583378","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623583378?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:00","pubTimestamp":1774954859,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nFWN40J0U3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AKTS","BK4148","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623300126","title":"Aktis Oncology, Inc. : H.c. Wainwright Raises Target Price to $33 From $30","url":"https://stock-news.laohu8.com/highlight/detail?id=2623300126","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623300126?lang=en_us&edition=fundamental","pubTime":"2026-03-31 18:18","pubTimestamp":1774952327,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nAZN4SO9G2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4148","BK4139","AKTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623328320","title":"Analysts Conflicted on These Healthcare Names: Aktis Oncology, Inc. (AKTS) and Ramsay Health Care (OtherRMSYF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2623328320","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623328320?lang=en_us&edition=fundamental","pubTime":"2026-03-31 07:40","pubTimestamp":1774914007,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aktis Oncology, Inc. (AKTS) and Ramsay Health Care (RMSYF). Aktis...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-aktis-oncology-inc-akts-and-ramsay-health-care-otherrmsyf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-aktis-oncology-inc-akts-and-ramsay-health-care-otherrmsyf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4185","BK4585","BK4588","BK4148","LU0128526141.USD","XBI","AKTS","LU0029874061.USD","XLV","HCSG","BK4139","BK4581","LABU","BK4137","RMSYF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623329204","title":"Aktis Oncology Receives US FDA Approval for AKY-2519 Investigational New Drug Applications","url":"https://stock-news.laohu8.com/highlight/detail?id=2623329204","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623329204?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:35","pubTimestamp":1774902934,"startTime":"0","endTime":"0","summary":"Aktis Oncology  said late Monday that the US Food and Drug Administration cleared its investigational new drug applications, allowing it to proceed to a phase 1b clinical trial of AKY-2519, expected to begin in mid-2026.AKY-2519 is a miniprotein radioconjugate targeting B7-H3, which is expressed in multiple solid tumor types including prostate and lung cancers, the company said.Results from the clinical imaging and dosimetry assessment of AKY-2519 in patients with various solid tumors are expected in mid-2026, the company added.The company said its cash position will fund its operations into 2029.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","AKTS","BK4148","BK4588","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623329993","title":"Aktis Oncology announces FDA clearance of AKY-25191 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2623329993","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623329993?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:17","pubTimestamp":1774901836,"startTime":"0","endTime":"0","summary":"Aktis Oncology (AKTS) announced the FDA cleared the investigational new drug applications for the company to proceed to a Phase 1b clinical trial w...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aktis-oncology-announces-fda-clearance-of-aky-25191-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aktis-oncology-announces-fda-clearance-of-aky-25191-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","BK4585","LABU","AKTS","BK4148"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623232674","title":"Aktis Oncology FY25 net loss widens to $64M; R&D expenses climb to $68M","url":"https://stock-news.laohu8.com/highlight/detail?id=2623232674","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623232674?lang=en_us&edition=fundamental","pubTime":"2026-03-31 04:05","pubTimestamp":1774901136,"startTime":"0","endTime":"0","summary":"Aktis Oncology posted a net loss of $64 million for 2025, widening from $44 million.Revenue rose to $6.5 million from $1.5 million, due to a full year of recognition under its Eli Lilly collaboration.R&D expenses climbed to $68 million from $41 million, driven by higher headcount and spending to advance AKY-1189 and AKY-2519.FDA cleared IND applications for AKY-2519, with Phase 1b initiation expected in mid-2026; AKY-1189 Phase 1b preliminary data are expected in Q1 2027.Pro forma cash was $562 million after January 2026 IPO net proceeds of about $335 million, with runway expected into 2029.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aktis Oncology Inc. published the original content used to generate this news brief on March 30, 20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL1tkp2P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2461242641.AUD","LU0323591593.USD","IE00BKDWB100.SGD","IE00BFSS8Q28.SGD","SG9999018857.SGD","LU1720051017.SGD","LU0203202063.USD","LU2237443549.SGD","IE0005OL40V9.USD","IE00BJT1NW94.SGD","IE0004445239.USD","LU0456855351.SGD","ELIL","BK4581","LU0079474960.USD","IE00B2B36J28.USD","SG9999014898.SGD","LU2361044865.SGD","LLYX","LLII","LU1232071149.USD","LU0708995401.HKD","LU1291159041.SGD","IE00BWXC8680.SGD","LU2746668461.USD","LU2237443382.USD","LU0320765992.SGD","LU2168563687.JPY","LU1983299246.USD","IE00B7KXQ091.USD","LU0106261372.USD","LU2089984988.USD","LU1988902786.USD","IE00BFTCPJ56.SGD","LU0787776722.HKD","LU0114720955.EUR","LU2111349929.HKD","LU1974910355.USD","LU2456880835.USD","LU1323610961.USD","LU2462157665.USD","LU2756315318.SGD","LU2471134879.HKD","LU2750360641.GBP","LU2168564065.EUR","SG9999014914.USD","LU0158827948.USD","LU2756315664.SGD","LU0203201768.USD","LU0820561909.HKD","LU0943347566.SGD","LU1804176565.USD","SGXZ51526630.SGD","BK4585","LU0096364046.USD","LU0234572021.USD","LU2023251221.USD","LU2236285917.USD","LU2552382215.SGD","IE00BJLML261.HKD","LU0097036916.USD","LU0786609619.USD","LU0823416689.USD","IE0002141913.USD","SG9999015945.SGD","LU1629891620.HKD","SG9999015978.USD","LU0210536198.USD","LU1868836591.USD","LU0820561818.USD","BK4599","LU2108987350.USD","LU1551013425.SGD","SGXZ31699556.SGD","LU2602419157.SGD","IE0009355771.USD","LLYZ","LU2264538146.SGD","LU0882574055.USD","SG9999015952.SGD","IE00BJJMRX11.SGD","LU1057294990.SGD","LU1069344957.HKD","LU1093756325.SGD","LU1868836914.USD","LU1917777945.USD","LU0094547139.USD","LU2237443465.HKD","LU1093756168.USD","LU2468319806.SGD","LU0238689110.USD","IE00BFSS7M15.SGD","LU0689472784.USD","LU2471134952.CNY","LU2750360997.AUD","SG9999013999.USD","IE00BJJMRZ35.SGD","LU1868837136.USD","LU2237443622.USD","IE00BKPKM429.USD","LU2491049909.HKD","BK4007","SG9999001176.USD","BK4148","LU0823434740.USD","LU1868836757.USD","LU0385154629.USD","BK4139","LU2360106947.USD","LU0061475181.USD","SG9999015986.USD","SG9999014880.SGD","LU2023250330.USD","LU2324357040.USD","LU0471298777.SGD","LU2552382058.USD","IE00B4R5TH58.HKD","LU0256863902.USD","LU2271345857.HKD","LU0109394709.USD","LU2896262040.SGD","LU0353189763.USD","LU0256863811.USD","LU0672654240.SGD","LU2471134523.USD","GB00BDT5M118.USD","LU0109391861.USD","LU0316494557.USD","LU0122379950.USD","LU1366192091.USD","LU2168564222.USD","LU2087625088.SGD","SG9999001176.SGD","LU0353189680.USD","LU1023059063.AUD","LU1720051108.HKD","LU2357305700.SGD","LU2417539215.USD","LU1127390331.HKD","LU0354030511.USD","LU2237443895.HKD","LU0882574139.USD","IE00B775H168.HKD","LU2023250504.SGD","LU2168564495.EUR","LU2746668974.SGD","LU0889565916.HKD","LU2112291526.USD","LU1035775433.USD","BK4534","SGXZ57979304.SGD","SG9999018865.SGD","LU2211815571.USD","LU1145028129.USD","LU2491050071.SGD","LU2237438978.USD","LU1064131342.USD","LU0058720904.USD","BK4588","LU2089283258.USD","AKTS","IE00B1BXHZ80.USD","LU2471134796.USD","LU0417517546.SGD","LU0198837287.USD","LU2089284900.SGD","SGXZ81514606.USD","LU0466842654.USD","LU1061106388.HKD","SGXZ99366536.SGD","LU0640476718.USD","IE00B4JS1V06.HKD","LU1548497426.USD","LU0471298694.HKD","LU1551013342.USD","LU1712237335.SGD","LU1989771016.USD","IE00BJJMRY28.SGD","LU0158827781.USD","IE0001KFT4U8.USD","LU0683600562.USD","LU2265009873.SGD","SG9999014906.USD","LU2063271972.USD","LU1267930730.SGD","LU0006306889.USD","LU1623119135.USD","LU2237443978.SGD","IE00B1XK9C88.USD","BK4533","LU0354030438.USD","LU1814569148.SGD","LU0964807845.USD","LU2106854487.HKD","SG9999017495.SGD","LU2491050154.USD","LU0320765059.SGD","LU1868837300.USD","IE00BK4W5L77.USD","LU2213496289.HKD","LU0820562030.AUD","IE0004445015.USD","LU2168564149.EUR","LU0432979614.USD","LU1280957306.USD","LU2028103732.USD","LU2361044949.HKD","LU2552382132.HKD","ELIS","LU0823434583.USD","IE00BN29S564.USD","IE00BK4W5M84.HKD","BK4516","LU0225283273.USD","LU0289739699.SGD","LU0266013472.USD","LU2361045086.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618628525","title":"This Aktis Oncology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2618628525","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618628525?lang=en_us&edition=fundamental","pubTime":"2026-03-09 19:17","pubTimestamp":1773055020,"startTime":"0","endTime":"0","summary":"Top analysts change outlook on top names. See all analyst rating changes on Benzinga's analyst ratings page. Consider AKTS stock based on analyst views.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/09/Analysts-Debate-Depreciation-Impact_0.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/09/Analysts-Debate-Depreciation-Impact_0.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/analyst-stock-ratings/downgrades/26/03/51122885/this-aktis-oncology-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-monday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/analyst-stock-ratings/downgrades/26/03/51122885/this-aktis-oncology-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-monday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BLSX","BK4148","BK4112","AKTS","BLSG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618647622","title":"Aktis Oncology Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2618647622","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618647622?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:32","pubTimestamp":1773052320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AKTS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 09, 2026 06:32 ET (10:32 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4148","AKTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618647838","title":"Aktis Oncology initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2618647838","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618647838?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:21","pubTimestamp":1773051693,"startTime":"0","endTime":"0","summary":"H.C. Wainwright initiated coverage of Aktis Oncology (AKTS) with a Buy rating and $30 price target The company is expanding the potential of target...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/aktis-oncology-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/aktis-oncology-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AKTS","BK4139","BK4148"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618274642","title":"Aktis Oncology, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating  and Target Price $30","url":"https://stock-news.laohu8.com/highlight/detail?id=2618274642","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618274642?lang=en_us&edition=fundamental","pubTime":"2026-03-09 18:17","pubTimestamp":1773051455,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nAZN4SK9N2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4148","AKTS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618064801","title":"U.S. RESEARCH ROUNDUP-Dow, Oracle, Shopify","url":"https://stock-news.laohu8.com/highlight/detail?id=2618064801","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618064801?lang=en_us&edition=fundamental","pubTime":"2026-03-09 15:34","pubTimestamp":1773041646,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Dow, Oracle, ShopifyMarch 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies on Monday, including Dow, Oracle ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260309:nL4N3ZX0MM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANAB","APC","CERT","CHRD","ORCS","DAWN","USAC","CORD","CWVX","MWH","CRWU","SHPD","FANG","HTO","GWRE","ORCL","AEYE","GCO","IE00BYQQ9H92.USD","EBS","BK4532","SHPU","ADBE","ADBG","AVTR","CTRA","LDOS","ORCU","EVRG","CRWG","DVN","FTRE","AKTS","ORCX","SHOP","EMN","OVV","DOW","HRI","CAT","LU1261432733.SGD","SNDX","DE","BROS","LU2083900584.USD","AVA","APA","CRWV","T","INSW"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2617552462","title":"Aktis Oncology’s NECTINIUM-2 Trial: A New Radiopharma Bet in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2617552462","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617552462?lang=en_us&edition=fundamental","pubTime":"2026-03-05 00:34","pubTimestamp":1772642077,"startTime":"0","endTime":"0","summary":"Aktis Oncology, Inc. ($AKTS) announced an update on their ongoing clinical study. Aktis Oncology Advances First-in-Human Radiopharma Trial in Solid...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aktis-oncologys-nectinium-2-trial-a-new-radiopharma-bet-in-solid-tumors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aktis-oncologys-nectinium-2-trial-a-new-radiopharma-bet-in-solid-tumors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4148","AKTS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614208836","title":"Aktis Oncology: Fast-Track Momentum and Pipeline Catalysts Underpin Buy Rating and $34 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2614208836","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614208836?lang=en_us&edition=fundamental","pubTime":"2026-02-25 18:06","pubTimestamp":1772013977,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Buy rating on Aktis Oncology, Inc., with a price target...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/aktis-oncology-fast-track-momentum-and-pipeline-catalysts-underpin-buy-rating-and-34-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/aktis-oncology-fast-track-momentum-and-pipeline-catalysts-underpin-buy-rating-and-34-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AKTS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614265687","title":"Aktis Oncology to Present at Upcoming March Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2614265687","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614265687?lang=en_us&edition=fundamental","pubTime":"2026-02-25 05:05","pubTimestamp":1771967100,"startTime":"0","endTime":"0","summary":"BOSTON, Feb.  24, 2026  (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to la","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/24/3244020/0/en/Aktis-Oncology-to-Present-at-Upcoming-March-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4148","AKTS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aktisoncology.com","stockEarnings":[{"period":"1week","weight":-0.0355},{"period":"1month","weight":0.3226},{"period":"3month","weight":-0.0533},{"period":"6month","weight":0.1161},{"period":"ytd","weight":0.1161}],"compareEarnings":[{"period":"1week","weight":0.0091},{"period":"1month","weight":0.1279},{"period":"3month","weight":0.0283},{"period":"6month","weight":0.0404},{"period":"1year","weight":0.2988},{"period":"ytd","weight":0.0488}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Akoustis Technologies, Inc., through its subsidiary, Akoustis, Inc., designs, develops, manufactures, and sells radio frequency (RF) filter products for the wireless industry in the Americas, Asia, Europe, and internationally. It operates in two segments, Fabrication Services and RF Filters. The Fabrication Services segment provides engineering review and backend packaging services. The RF Filters segment sells amplifier and filter products. It offers RF filters for the wireless industry, such as smartphones and tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, and military and defense applications. The company also sells complementary surface acoustic wave resonators, crystal (Xtal) resonators and oscillators, and ceramic products; and provides back-end semiconductor supply chain services. Akoustis Technologies, Inc. is headquartered in Huntersville, North Carolina.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.07242},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.009578},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.089105},{"month":4,"riseRate":0.25,"avgChangeRate":-0.011983},{"month":5,"riseRate":0.5,"avgChangeRate":-0.07198},{"month":6,"riseRate":0.5,"avgChangeRate":-0.041124},{"month":7,"riseRate":0.25,"avgChangeRate":-0.065017},{"month":8,"riseRate":0.5,"avgChangeRate":-0.046698},{"month":9,"riseRate":0.375,"avgChangeRate":-0.092023},{"month":10,"riseRate":0.375,"avgChangeRate":-0.160528},{"month":11,"riseRate":0.625,"avgChangeRate":0.149228},{"month":12,"riseRate":0.375,"avgChangeRate":0.01269}],"exchange":"NASDAQ","name":"Aktis Oncology","nameEN":"Aktis Oncology"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aktis Oncology(AKTS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Aktis Oncology(AKTS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Aktis Oncology,AKTS,Aktis Oncology股票,Aktis Oncology股票老虎,Aktis Oncology股票老虎国际,Aktis Oncology行情,Aktis Oncology股票行情,Aktis Oncology股价,Aktis Oncology股市,Aktis Oncology股票价格,Aktis Oncology股票交易,Aktis Oncology股票购买,Aktis Oncology股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aktis Oncology(AKTS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Aktis Oncology(AKTS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction